Janus Henderson Group PLC Travere Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 31,813 shares of TVTX stock, worth $605,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,813
Previous 32,181
1.14%
Holding current value
$605,401
Previous $248,000
5.24%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TVTX
# of Institutions
187Shares Held
89.8MCall Options Held
137KPut Options Held
184K-
Black Rock Inc. New York, NY7.64MShares$145 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$143 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$140 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$126 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$85.3 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.22B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...